Evolution of the Thienopyridine Class of Inhibitors of IκB Kinase-β: Part I: Hit-to-Lead Strategies
Authors:
- 20 April 2006
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (10) , 2898-2908
Abstract
High-throughput screening is routinely employed as a method for the identification of novel hit structures. Large numbers of active compounds are typically procured in this way and must undergo a rigorous validation process. This process is described in detail for a collection of screening hits identified as inhibitors of IκB kinase-β (IKKβ), a key regulatory enzyme in the nuclear factor-κB (NF-κB) pathway. From these studies, a promising hit series was selected. Subsequent lead generation activities included the development of a pharmacophore hypothesis and structure−activity relationship (SAR) for the hit series. This led to the exploration of related scaffolds offering additional opportunities, and the various structural classes were comparatively evaluated for enzyme inhibition, selectivity, and drug-like properties. A novel lead series of thienopyridines was thereby established, and this series advanced into lead optimization for further development.Keywords
This publication has 31 references indexed in Scilit:
- Lead Generation: Sowing the Seeds for Future SuccessChimia, 2004
- The IKK NF-κB system: a treasure trove for drug developmentNature Reviews Drug Discovery, 2004
- Nonleadlikeness and leadlikeness in biochemical screeningDrug Discovery Today, 2003
- Computational methods for the prediction of ‘drug-likeness’Drug Discovery Today, 2000
- How NF-κB is activated: the role of the IκB kinase (IKK) complexOncogene, 1999
- Recognizing molecules with drug-like propertiesCurrent Opinion in Chemical Biology, 1999
- Limb and Skin Abnormalities in Mice Lacking IKKαScience, 1999
- Evolution of a Protein Fold in VitroScience, 1999
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 1997
- Pyrido[3',2':4,5]thieno[3,2-d]-N-triazines: a new series of orally active antiallergic agentsJournal of Medicinal Chemistry, 1984